Oncotelic Therapeutics OTLC
OTC OTLC
$0.02 +0.00 (+0.00%)
At close: Oct 15, 2026 · 4:00 PM EDT

Oncotelic Therapeutics (OTLC) EBITDA Margin (2012 - 2021)

Updated

Oncotelic Therapeutics (OTLC) reported EBITDA Margin of -1812.87% for FY2021, down 1398.11 percentage points from -414.77% in FY2020.

Analysis

Oncotelic Therapeutics (OTLC) EBITDA Margin (2012 - 2021) Analysis & Trends

Dating back to FY2012, Oncotelic Therapeutics' EBITDA Margin record includes 4 years.

  • The FY2021 figure ranks as the lowest annual EBITDA Margin since FY2013.
  • According to Business Quant data, EBITDA Margin came in at -414.77% in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,109.83 Bn 1,078.42 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 610.61 Bn 529.14 Bn 17.26 Bn 35.95%
3 AbbVie 500.66 Bn 473.77 Bn 12.70 Bn 49.01%
4 Merck 354.64 Bn 309.02 Bn 12.21 Bn 6.02%
5 Novartis Ag 291.14 Bn 255.13 Bn 11.24 Bn -
6 Astrazeneca 254.18 Bn 227.87 Bn 12.86 Bn 33.11%
7 Amgen 229.46 Bn 184.86 Bn 7.24 Bn 46.01%
8 Gilead Sciences 190.33 Bn 164.53 Bn 6.22 Bn -124.26%
9 Pfizer 167.92 Bn 114.57 Bn 10.94 Bn 39.16%
10 Oncotelic Therapeutics 8.28 Mn 7.42 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 -320.26%
Jun 30, 2020 12.24%
Mar 31, 2020 -413.46%
Sep 30, 2013 -2,757.89%
Dec 31, 2012 -3,880.95%
Mar 31, 2012 -1,625.44%
API Access

Oncotelic Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=OTLC&period=max&api_key=YOUR_API_KEY